This novel monoclonal antibody, Pritoxaximab – formerly known as DXX00601 – represents significant promise within the therapy of severe hemolytic disease (TRALI). Developed by scientists, Pritoxaximab works by https://dirstop.com/story29637805/pritoxaximab-a-deep-dive-into-dxx00601-s-potential